6533b831fe1ef96bd129973b
RESEARCH PRODUCT
Antithrombotic Therapy in COVID-19: Systematic Summary of Ongoing or Completed Randomized Trials
Sahil A. ParikhMary CushmanBehnood BikdeliBehnood BikdeliJeffrey I. WeitzJohn W. EikelboomGregg W. StoneGregory PiazzaJean M. ConnorsBenjamin W. Van TassellHessam KakavandHarlan M. KrumholzBeverley J. HuntSamuel Z. GoldhaberDavid JiménezSeyed Hossein HosseiniHamid AriannejadMichelle SholzbergMichelle SholzbergStavros KonstantinidesStavros KonstantinidesAjay J. KirtaneManuel MonrealGregory Y.h. LipGregory Y.h. LipElahe Kordzadeh-kermaniSepehr JamalkhaniSepehr JamalkhaniParham SadeghipourAzita Hajhossein TalasazAzin GheymatiMaryam Aghakouchakzadehsubject
medicine.medical_specialty2019-20 coronavirus outbreakCoronavirus disease 2019 (COVID-19)Hospitalized patientsbusiness.industrySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)law.inventionClinical trialRandomized controlled triallawAntithromboticmedicineIllness severityIntensive care medicinebusinessdescription
ABSTRACTEndothelial injury and microvascular/macrovascular thrombosis are common pathophysiologic features of coronavirus disease-2019 (COVID-19). However, the optimal thromboprophylactic regimens remain unknown across the spectrum of illness severity of COVID-19. A variety of antithrombotic agents, doses and durations of therapy are being assessed in ongoing randomized controlled trials (RCTs) that focus on outpatients, hospitalized patients in medical wards, and critically-ill patients with COVID-19. This manuscript provides a perspective of the ongoing or completed RCTs related to antithrombotic strategies used in COVID-19, the opportunities and challenges for the clinical trial enterprise, and areas of existing knowledge, as well as data gaps that may motivate the design of future RCTs.
year | journal | country | edition | language |
---|---|---|---|---|
2021-01-06 |